Daewoong Pharmaceutical Signs Exclusive Global Technology Introduction Contract for 4-Week Long-Acting Semaglutide Injection for Obesity

Daewoong Pharmaceutical entered into an exclusive global technology introduction contract with Tion Lab Therapeutics for a semaglutide-based 4-week long-acting injectable for obesity (contract date: 2026-05-21).
Under the contract, Daewoong receives exclusive rights to develop, manufacture, obtain approval, and commercialize the product worldwide excluding South Korea, with the right to sublicense to third parties.
The contract term is the later of 15 years from the first commercial sale or patent expiry, subject to early termination under certain conditions.
Financial terms (upfront payment, milestones, royalties) are undisclosed for confidentiality reasons, with a retention period until 2044-08-19.
The core technology controls initial burst release from a depot formulation, enabling once-every-4-week dosing, significantly reducing injection frequency.

ADVERTISEMENT (250px+)

Filing: Major Management Matters Related to Investment Decision (Major Management Matters of Subsidiary) (Execution of Technology Introduction Agreement for Semaglutide for Obesity Treatment (4-week long-acting injectable))
Company: Daewoong (003090)
Submission: Daewoong Co., Ltd.
Receipt: 05-21-2026
Under KRX KOSPI Market Division